<DOC>
	<DOCNO>NCT01613846</DOCNO>
	<brief_summary>Sorafenib pazopanib effective promising treatment advance Renal Cell Carcinoma ( RCC ) . Both drug register indication . No prospective comparative data advance RCC ( indication ) publish . A search clinicaltrials.gov database reveal plan ongoing study . As sequential therapy standard treatment advance RCC important evaluate clinical trial value different sequential strategy . This need do every time new agent introduce treatment armamentarium . As data yet sequential use sorafenib follow pazopanib vice versa , sequence , however , certainly use daily practice , require examine efficacy safety sequential approach clinical trial randomize setting . Therefore , investigator design open randomize study patient previously treat advanced RCC . Suitable patient randomize ( 1:1 ) 2 group .</brief_summary>
	<brief_title>Phase III Sequential Open-label Study Evaluate Efficacy Safety Sorafenib Followed Pazopanib Versus Pazopanib Followed Sorafenib Treatment Advanced / Metastatic Renal Cell Carcinoma ( SWITCH-II )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Patients metastatic / advance RCC ( histology ) , suitable cytokine therapy study medication constitute firstline treatment . For cytokine unsuitability least one follow criterion must fulfilled* : Age 66 88 year Nonclear cell histology RCC Intermediate risk accord MSKCC score ECOG ≥ 1 &gt; 1 organ metastasis + &lt; 24 month diagnosis establish indication interleukin2therapy ECOG ≥ 1 `` unable carry normal activity active work '' ( Karnofsky Index 70 % ) Creatinine ≥ 1x ULN &lt; 2x ULN Total bilirubin ≥ 1x ULN &lt; 1.5x ULN Present autoimmune disease Patients might require steroid Hypersensitivity cytokine Severe organic disease , interfere in/exclusion criterion Switch2 study Nonsymptomatic brain metastasis Severe lung disease ( e.g . PAH , COPD ) Pa O2 &lt; 60 mmHg rest 2 . Age ≥ 18 ≤ 85 year 3 . Karnofsky Index ≥ 70 % ( see appendix 15.1 ) 4 . MSKCC prognostic score ( 2004 ) , low intermediate ( see appendix 15.2 ) 5 . Life expectancy least 12 week 6 . Subjects least one unidimensional ( RECIST 1.1 ) measurable lesion . Lesions must measure CT/MRI scan 7 . Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior start therapy : hemoglobin &gt; 9.0 g/dl absolute neutrophil count ( ANC ) &gt; 1,500 µl Platelet count ≥ 100,000 / µl total bilirubin &lt; 1.5x upper limit normal ( Note : Subjects Gilbert ' Syndrome eligible total bilirubin &lt; 3.0 X ULN direct bilirubin ≤ 35 % ) . ALAT ASAT &lt; 2.5x upper limit normal ( Note : concomitant elevation bilirubin an ASAT/ALAT 1.0x upper limit normal permit ) . Alkaline phosphatase &lt; 4x upper limit normal PTINR/aPTT &lt; 1.2x upper limit normal ( Patients therapeutically anticoagulated agent coumadin heparin allow participate provide INR stable within recommended range desire level anticoagulation prior evidence underlying abnormality parameter exist ) . Serum creatinine &lt; 2x upper limit normal 8 . Written Informed Consent 1 . History cardiac disease : congestive heart failure &gt; NYHA class 2 LVEF baseline echocardiography &lt; 50 % , ( echocardiography optional ) ; active CAD ( MI 6 month prior study entry allow ) ; cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) 2 . Uncontrolled hypertension ( define blood pressure ≥ 150 mmHg systolic and/or ≥ 90 mmHg diastolic medication ) . 3 . History HIV infection chronic hepatitis B C 4 . 4 . Active clinically serious infection ( &gt; grade 2 NCICTC version 4.03 ) 5 . Symptomatic metastatic brain meningeal tumor ( unless patient &gt; 6 month definitive therapy , negative imaging study within 4 week study entry clinically stable respect tumor time study entry ) 6 . Patients seizure disorder require medication ( steroids antiepileptic ) 7 . Patients evidence history bleed diathesis 8 . History organ allograft 9 . Major surgery within 4 week start study 10 . Autologous bone marrow transplant stem cell rescue within 4 month study start . 11 . Any significant condition increase risk bleeding , include , limited active peptic ulcer disease , inflammatory bowel disease , know intraluminal endobronchial metastatic lesion and/or lesion infiltrate major pulmonary vessel risk bleeding , presence nonhealing wound trauma within 4 week prior first dose investigational drug 12 . History cerebrovascular accident include transient ischemic attack ( TIA ) , pulmonary embolism untreated deep vein thrombosis ( DVT ) within past 6 month ( Note : Subjects recent DVT treat therapeutic anticoagulating agent least 6 week eligible ) 13 . Corrected QT Interval ( QTc ) &gt; 480 msec 14 . Untreated hypothyroidism 15 . Patients undergoing renal dialysis 16 . Previous concurrent cancer distinct primary site histology cancer evaluate study EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis &amp; T1 ] cancer curatively treat &gt; 3 year prior study entry 17 . Pregnant breastfeeding patient . Women childbearing potential must negative pregnancy test perform within 7 day start treatment . Both men woman enrol trial must use adequate barrier birth control measure ( Pearl Index &lt; 1 ) course trial 3 month completion trial 18 . Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result 19 . Any condition unstable could jeopardize safety patient compliance study 20 . Patients unable swallow oral medication 21 . Clinically significant gastrointestinal abnormality may affect absorption investigational product 22 . Known allergy Votrient Nexavar ( i.e . active substance one constituent ) 23 . Prior exposure study drug . 24 . Investigational drug therapy within 4 week study entry . 25 . Use biologic response modifier , GCSF hematopoietic growth factor , within 3 week study entry 26 . Radiotherapy within 3 week start study drug plan radiotherapy study 27 . Concomitant medication : Any condition discretion investigator precludes compliance concomitant therapy restriction describe .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>